Cargando…

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk

BACKGROUND AND AIMS: The LDL cholesterol (LDL-C) treatment goals recommended by the 2019 ESC/EAS guidelines are only achieved in a minority of patients. The study objective was to estimate the impact of bempedoic acid treatment on LDL-C target attainment, drug costs, and atherosclerotic cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katzmann, Julius L., Becker, Christian, Bilitou, Aikaterini, Laufs, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612573/ https://www.ncbi.nlm.nih.gov/pubmed/36301892 http://dx.doi.org/10.1371/journal.pone.0276898

Ejemplares similares

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk
por: Laufs, Ulrich, et al.
Publicado: (2016)

Why doesn’t high cholesterol hurt?
por: Katzmann, Julius L., et al.
Publicado: (2019)

Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
por: Pradhan, Akshyaya, et al.
Publicado: (2023)

Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
por: Katzmann, Julius L., et al.
Publicado: (2020)

Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins
por: Fox, Kathleen M., et al.
Publicado: (2017)

Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
por: Alam, Uazman, et al.
Publicado: (2021)

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients
por: Toplak, Hermann, et al.
Publicado: (2023)

Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
por: Jialal, Ishwarlal, et al.
Publicado: (2023)

Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk
por: Katzmann, Julius L, et al.
Publicado: (2018)

An Update on New Cholesterol Inhibitor: Bempedoic Acid
por: Kulshreshtha, Mayank
Publicado: (2022)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study
por: Ray, Kausik K., et al.
Publicado: (2021)

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
por: Laufs, Ulrich, et al.
Publicado: (2019)

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins
por: McQueen, R. Brett, et al.
Publicado: (2022)

Statins and Bempedoic Acid: Different Actions of Cholesterol Inhibitors on Macrophage Activation
por: Linnenberger, Rebecca, et al.
Publicado: (2021)

Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias
por: Vrablík, Michal, et al.
Publicado: (2023)

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
por: Pinkosky, Stephen L., et al.
Publicado: (2016)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
por: Katzmann, Julius L., et al.
Publicado: (2020)

Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis
por: Lin, Yingfeng, et al.
Publicado: (2022)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

Bempedoic acid for the treatment of dyslipidemia
por: Marrs, Joel C, et al.
Publicado: (2020)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
por: Alwhaibi, Monira, et al.
Publicado: (2019)

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
por: Iyen, Barbara, et al.
Publicado: (2021)

The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment
por: März, Winfried, et al.
Publicado: (2023)

The Role of Cumulative LDL Cholesterol in Cardiovascular Disease Development in Patients with Familial Hypercholesterolemia
por: Korneva, Victoria, et al.
Publicado: (2022)

Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Bempedoic acid: what prospective uses?
por: Jacomelli, Ilaria, et al.
Publicado: (2023)

A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
por: Srivastava, Rai Ajit K.
Publicado: (2023)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

THU584 Comparison Of The Cardiovascular Benefits Of Bempedoic Acid With Statins- Analysis By The Cholesterol Treatment Trialists’ Methodology
por: Lincoff, A Michael, et al.
Publicado: (2023)

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
por: Banach, Maciej, et al.
Publicado: (2020)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
por: Armstrong, Shannon O, et al.
Publicado: (2019)

Pharmacokinetics of bempedoic acid in patients with renal impairment
por: Amore, Benny M., et al.
Publicado: (2021)

Correction to: Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v9evdnurefjk04eov5tk21rk1h